HydroCoils can be used effectively and safely to treat intracranial DAVFs transvenously. The volume expansion of Hydrocoils may have significant advantage over bare platinum coils given the large venous spaces that need to be filled. The use of HydroCoils may decrease the procedure time and consequently reduce the radiation dose to the patient.
Introduction
Cranial dural arteriovenous fistulas (DAVFs) are uncommon and present with a variety of clinical signs and symptoms depending on their angioarchitecture. DAVFs with cortical venous reflux may become symptomatic due to venous congestion or intracranial hemorrhage. The annual neurological event rate is 15% and mortality rate is 10.4% in patients with DAVFs and cortical venous reflux 1 . Cranial DAVFs can cause venous congestion in the orbit resulting in proptosis, chemosis, double vision and progressive visual loss 2 . Treatment of DAVFs with cortical venous reflux is indicated to prevent hemorrhage, progressive ophthalmologic and/or neurological deficit 3 .
Embolization using a transarterial approach has been shown to have a relatively low cure rate due to the multiplicity of the feeding arteries and the difficulty in reaching the venous side of the fistula 2, 4 . Embolization using a transvenous approach has been used for selective Summary Intracranial dural arteriovenous fistulas (DAVF) with cortical venous reflux may become symptomatic due to venous congestion or intracranial hemorrhage. Venous congestion in the orbit can also occur resulting in proptosis, chemosis, double vision and progressive visual loss. The transvenous approach has been used for selective disconnection of the venous drainage to eliminate the venous congestion and future risk of intracranial bleeding and/or neurological deficit. Hydrogel coated coils (Hydro-Coil®) expand after contact with blood causing the coils to swell up to five to 11 times a standard 10-system bare platinum coil. Due to this property, HydroCoils could have an advantage over platinum coils in the transvenous approach to embolization of DAVFs.
Ten patients with symptomatic cranial DAVF underwent a transvenous embolization using HydroCoils as the only embolic agent or in a combination with bare platinum coils. The patients' characteristics, symptoms, angioarchitecture of the DAVF, treatment, complications and results were analyzed.
All the treated DAVFs were disconnected at the end of the procedure. All the patients with orbital symptoms had complete or significant improvement. There were no periprocedural complications. Nine patients had radiological follow-up showing cure.
Transvenous Treatment of Cranial Dural Arteriovenous Fistulas with Hydrogel Coated Coils 320 disconnection of the venous side to eliminate the venous congestion and therefore the risk of death and/or permanent neurological deficit [4] [5] [6] . When catheterization is possible, transvenous embolization is associated with a high rate of permanent occlusion 6 .
A variety of embolic agents have been used in the treatment of DAVFs including platinum coils which have been used with good results 4, 6, 7 . Recently the HydroCoil Embolic System (HES; MicroVention, Aliso Viejo, CA) has become available. The HydroCoil expands when it comes in contact with blood 7 . This could potentially be beneficial in the treatment of DAVFs when large venous spaces have to be filled. All the procedures were performed under general anesthesia. 5F sheaths were positioned bilaterally, one in the femoral artery and the other in the femoral vein using the arterial side to perform simultaneous road map and control angiograms during the procedure. Full heparinization was performed with a bolus dose of 100 mg/kg and the Activated Clotting Time (ACT) levels were kept between 250-350 seconds. A 5F diagnostic catheter was positioned selectively in the internal or external carotid artery depending on the arterial supply to the DAVF. Selective catheterization of the superior cava vein was performed with a 5F or 6F Envoy Guiding Catheter (Cordis Endovascular Systems, Miami, FL) and then a microcatheter Prowler14, Prowler Plus (Cordis Endovascular Systems, Miami, FL) or Excelsior 14 (Boston Scientific/Target Therapeutics, Natick, MA) and a microguidewire Transcend Platinum Tip or Soft Tip (Scientific/Target Therapeutics, Natick, MA).
The cavernous sinus was approached transfemorally either through the inferior petrosal sinus (two cases) or the superior ophthalmic vein (three cases). Pial veins of the deep venous system were accessed in two cases via a transfemoral-transverse sinus (TS) approach. One patient with a TS DAVF was treated transfemorally and two patients with TS DAVF location required a direct burr hole over the si- nus for direct puncture. In two cases transarterial embolization was initially attempted unsuccessfully before the transvenous approach was performed. HydroCoils were used as the only embolic agent or in a combination with bare platinum coils.
Results
Ten patients, four male/six female (mean age 65.4 years) with DAVFs were treated transvenously with HydroCoils ( Table 1 ). The locations of the DAVFs were as follows: cavernous sinus (CS) unilaterally in four patients; CS bilaterally in one, transverse sinus in three and the tentorial edge in two.
According to the Borden classification three cases were Type 1 (no cortical venous reflux), five were Type 2 (indirect cortical venous reflux) and two were Type 3 (direct cortical venous reflux) 3 .
All five patients with cavernous sinus fistulas had symptoms related to orbital venous congestion ( figure 1) . These patients presented with bilateral or unilateral chemosis or diplopia and three patients had unilateral eye proptosis. Four of these patients were treated within two to four months of their clinical onset of symptoms and one patient was referred after six months of diplopia and visual loss.
One patient (patient No. 3, Table 1 ) had brain stem symptoms from a pontine hemorrhage. Initial assessment revealed diplopia, disarthria, and right side sensory loss (figure 2).
All the DAVFs were cured (with disconnection of the arteriovenous shunt) on the control angiogram performed at the end of the procedure. The number of HydroCoils used was from four to 13 ( Table 1 ). All the patients with orbital symptoms had significant improvement within three to 24 hours following the procedure ( figure 3 ). There were no periprocedural related complications. Clinical follow-up was performed in all patients and radiological follow-up, either with DSA or gadolinium-enhanced MRA was available in nine patients be- tween two and ten months after the procedure 8 . In all cases the radiological follow-up showed no recurrence of the fistula. Patients with gadolinium-enhanced MRA follow-up had had both DSA and gadolinium-enhanced MRA before the treatment. One patient with orbital symptoms related to Borden type 1 DAVF was followed only clinically with complete recovery of the neurological symptoms.
Discussion
Various embolic agents have been used to achieve venous disconnection of DAVFs including liquid embolic agents, silk sutures, detachable balloons, fibered coils and standard platinum detachable coils 2,4,6 . Limitations of the transvenous approach are related to access and embolic materials 6 . Bucrylates provide good long term results but are associated with a higher risk of neurological deficit due to the potential embolization of multiple arterial and venous anastomosis 4 . In addition, the use of bucrylates may directly damage the vascular supply to the cranial nerves (e.g. in the cavernous sinus) 4 . Platinum coils are currently the most widely used material for venous disconnection due to their ease of use. The disadvantage of the platinum coils is that often a great number of coils need to be deployed to fill the large venous spaces.
Klish et Al reported a series of 31 patients treated transvenously for direct carotid-cavernous and intracranial dural arteriovenous fistulae of which 25 cases were true DAVFs 6 . Eleven DAVFs where located in the CS and 14 were on the transverse or superior sagittal sinus. Seven patients (28%), with two DAVFs located in the CS, had incomplete results at the end of the endovascular procedure. Nine patients (36%), three in the CS, suffered from periprocedural complications.
Roy et Al reported a series of 22 patients diagnosed with DAVFs, 11 located in the CS, eight in the transverse sinus, two in the inferior petrosal sinus and one intradiploic fistula 4. Sixteen patients were treated with a single transvenous approach and six with a combined arterial and venous approach. A complete disconnection of the DAVF was achieved at the end of the procedure in only four (19%) and 17 were cured on late follow-up. One transvenous treatment (4.5%) failed to disconnect the DAVF with persistence at the eight month fol-low-up. The long term cure rate was 95.5% and included six patients that required additional transarterial treatment. Eight transient (36%) and one permanent (4.5%) complication occurred in patients treated transvenously in this series.
Clinical studies clearly indicate that DAVFs are difficult to treat endovascularly. Even when the venous catheterization is successful complete results are achieved in 42% to 80% of published series. The risk of complications is 36%-40% 6 . Cranial nerve palsy has been reported as a result of transvenous occlusion of the cavernous sinus 4,6 . CS thrombosis, glaucoma, central retinal vein thrombosis and increased pressure in the CS related to balloon or coil overpacking are thought to be the reason for these cranial nerve palsies 5, 6 .
The HydroCoils expand after contact with blood causing the coils to swell up to five to 11 times compared with a standard 10-system platinum coil. Due to their swelling property, HydroCoils could have an advantage over platinum coils expanding to fill a larger volume of the vessel lumen. Case reports using Hydro-Coils for aneurysm coiling and parent vessel occlusion have shown good results with a low complication rate 7, [9] [10] [11] .
Morsi et Al reported a patient treated with transvenous occlusion of a cavernous sinus DAVF with the use of HydroCoils. Good results were achieved with complete venous disconnection and no periprocedural complications. One case of transarterial embolization of the venous component with a mixture of hydrocoils and bare platinum coils of a DAVF has also been reported 12 .
Experimental studies demonstrate that in vitro measurements of the pressure inside a saccular aneurysm filled with HydroCoils and perfused with a physiologically pulsatile flow show that the expansion of the hydrated polymer does not contribute to any changes in the intraaneurysmal fluid pressure. This is shown in cases when the estimated volume of the packing is as high as 93% of the aneurysmal sac 13 . We believe that the swelling properties of Hy-droCoils (greater volume packing without increasing the intravascular pressure) may prevent cranial nerve damage related to coil overpacking and sinus and/or ophthalmic vein thrombosis when used in DAVF with cavernous sinus location. This is supported by the current series where all patients had a signifi-cant improvement or cure of their symptoms. In addition, by using fewer coils the amount of radiation per case could potentially be reduced although we cannot prove this with the current data.
However, in our series three DAVFs required seven or fewer coils to achieve a complete cure which in our experience is quite uncommon in transvenous treatment of DAVFs. A recent study has shown that radiation was reduced in aneurysm treatment using Hydrocoils when compared with bare platinum coils 14 .
Conclusions
Hydrogel coated platinum coils can be used effectively and safely to treat cranial DAVFs through a transvenous approach. The volume expansion of these coils has potentially a significant advantage over bare platinum coils given the large venous spaces that need to be filled. In addition to the efficacious closure of the DAVF, HydroCoil embolization may help reduce procedure time and therefore radiation exposure.
